Pharmaceutical giants AstraZeneca and Eli Lilly have paused or reconsidered significant UK investments amid industry headwinds. AstraZeneca halted a $271 million Cambridge research site expansion, while Eli Lilly remains uncertain about the Gateway Labs incubator plans. These developments reflect broader concerns about the UK life sciences environment including government support and market outlook, raising implications for biopharma R&D and job markets across the region.